Introduction. The availability of highly active antiretroviral therapy has altered the epidemic of human immunodeficiency virus infection among individuals with access to medical care. The Centers for Disease Control and Prevention and other public health authorities have reported decreases in both morbidity and mortality among HIV-infected patients. As Dr. Sepkowitz documents, however, opportunistic infections continue to occur in spite of antiretroviral therapy and prophylaxis. ''Breakthrough'' infections often present atypically, and thus the clinician must be alert to the changing picture of common infections impacting patients with advanced immunosuppression. Dr. Sepkowitz has reviewed the available literature and suggests a need to continue to document the atypical presentations of common opportunistic diseases in these patients.
In 1996, 68,473 new cases of AIDS were reported to the tions (OIs) in persons infected with human immunodeficiency virus (HIV) [2] , which were updated in 1997 [3] . The strongest Centers for Disease Control and Prevention (CDC), including 29,227 (43%) due to AIDS-indicator conditions [1] . Overall, recommendations concerned strategies to prevent Pneumocystis carinii pneumonia (PCP) and infections due to Toxoplasma the CDC estimates that Ç60,000 AIDS-related opportunistic illnesses have occurred each year in the United States since gondii, Mycobacterium tuberculosis, M. avium complex (MAC), Streptococcus pneumoniae, and varicella zoster virus 1992. Despite the large number of opportunistic conditions and the bewildering array of diseases described, most illness is [3] . Routine prophylaxis for cytomegalovirus, candidal, and endemic fungal diseases was considered indicated only in uncaused by a relatively small handful of pathogens, including Pneumocystis carinii, cytomegalovirus, various fungi, and myusual circumstances. Secondary prophylaxis was strongly recommended for PCP and infections with T. gondii, MAC, cytocobacteria; conditions such as the wasting syndrome and dementia; and neoplastic diseases, including Kaposi's sarcoma megalovirus, Salmonella species, Cryptococcus neoformans, and endemic fungi [3] . and lymphoma.
Therefore, in 1995, the United States Public Health Service Despite targeted and effective prophylaxis and despite the effect of potent antiviral therapies on the type and frequency (USPHS) and the Infectious Diseases Society of America (IDSA) issued guidelines for prevention of opportunistic infecof hospital admissions [4 -6] , opportunistic infections continue to occur. Most reports of trials examining a specific approach to the prevention of an opportunistic infection (prophylaxis studies) focus on two outcomes of interest: (1) the quantitative For the clinician, however, this last effect may be the most induction and BAL was similar (60% -70%). Another report suggested that chest radiographic features may be atypical and important, because the clinical presentation of an opportunistic infection in a patient receiving targeted prophylaxis may may include lobar as well as nondiffuse bilateral changes [13] . A recent report of cutaneous pneumocystosis documented the not resemble the opportunistic infection in a patient not receiving prophylaxis. In addition, potent protase-inhibitorpotential for extrapulmonary pneumocystosis in persons whose dapsone therapy fails [14] . containing antiviral regimens also may fundamentally alter the presentation and natural history of OIs [7] , further compliTrimethoprim-sulfamethoxazole. The clinical characteristics of PCP among patients whose trimethoprim-sulfamethoxacating diagnosis.
I therefore will review reports describing qualitative changes zole prophylaxis fails have not been described. in the presentation of common opportunistic infections in persons whose targeted prophylaxis fails. I will exclude failures Toxoplasmosis of secondary therapy, since the diagnostic dilemma facing the clinician in such a setting is far less acute. Recognition of the Trimethoprim-sulfamethoxazole is recommended as prophylaxis for both PCP and toxoplasmosis [3] , and it decreases rates potentially attenuating effects of failed prophylaxis is essential for clinicians caring for HIV-infected patients in the years of bacterial sinopulmonary disease as well. One report from France described breakthrough toxoplasmosis in two men reahead.
ceiving trimethoprim-sulfamethoxazole prophylaxis [15] . Both had low CD4 cell counts and protracted fever. Extensive workWell-Described Atypical Presentations up included multiple blood cultures and radiographic examinations, as well as CT scans of the brain. All tests were negative.
Pneumocystis carinii Pneumonia
Eventually, PCR and blood cultures demonstrated T. gondii. The diagnosis was verified by a clinical response to targeted In the absence of prophylaxis, PCP in patients with HIV infection typically presents as an indolent illness with constituantitoxoplasmosis therapy (clindamycin with pyrimethamine). Thus, toxoplasmosis in these patients receiving prophylaxis tional as well as respiratory symptoms that may extend 1 month or longer. Diffuse bilateral interstitial infiltrates, hypoxemia, presented not as a classic brain abscess but rather as a fever of unknown origin associated with parasitemia. and an elevated lactic dehydrogenase level further suggest the disease. The diagnosis can readily be made by examination of an induced sputum or bronchoalveolar lavage specimen.
Mycobacterium avium Complex (MAC)
Currently, there are three prophylactic agents commonly used to prevent PCP among patients with AIDS: aerosol penThree agents are approved for prophylaxis against disseminated MAC infection: rifabutin, clarithromycin, and azithrotamidine, dapsone, and trimethoprim-sulfamethoxazole. Because none of the three is completely effective and because PCP mycin. Even with optimal prophylaxis, however, breakthrough occurs in 3% -12% of patients, depending on the regimen used. is a common illness, ''breakthrough'' cases are encountered relatively often. In many circumstances, the clinical presentaIn a large series, patients whose rifabutin prophylaxis failed were found to have reduced fever and fatigue, higher hemoglotion and approach to diagnosis have been altered by the failed prophylactic regimen.
bin levels, lower alkaline phosphatase levels, and an improved Karnofsky score, when compared with placebo-control patients Aerosol pentamidine. Numerous reports have described the atypical features that may be encountered when a patient rewho developed MAC infection [16] . . Elevation of the alkaline phosphatase level, however, was seen in been described. Thus, the radiologic appearance of and diagnostic approach to PCP are substantially altered by use of only 4% overall, a rate significantly lower than expected. In addition, while all azithromycin-treated patients with breakaerosol pentamidine.
Dapsone. Unlike aerosol pentamidine, the clinical features through MAC infection developed symptoms, symptoms were seen in only 56% of those receiving combination rifabutin/ of failed dapsone prophylaxis are not well-characterized. A report comparing PCP developing in patients receiving aerosol azithromycin prophylaxis. This suggests that the most potent prophylactic regimen (with rifabutin/azithromycin) may have pentamidine vs. those receiving dapsone found similar clinical presentations, including respiratory complaints and chest radiosuppressed symptoms for many, even when the regimen ultimately failed. graphic features [12] . In addition, the sensitivity of sputum / 9c4a$$ap07
03-12-98 08:31:23 cidas UC: CID with individual-patient noncompliance [21, 22] . Primary or secondary prophylaxis for both herpes simplex and varicella zoster virus with acyclovir is a relatively common Tuberculosis practice. One report described the clinical appearance of acyclovir-resistant varicella zoster virus infection in four paLittle has been written about the clinical characteristics of tients who had received many months of chronic acyclovir tuberculosis in patients whose isoniazid prophylaxis fails, alprophylactic therapy [19] . The authors reported culture-proven though the microbiological consequences -namely, the emeracyclovir-resistant varicella zoster virus infection, presenting gence of resistance -have been much discussed. In a recent as atypical hyperkeratotic verrucous papules in a disseminated report from Nairobi, 48 cases of tuberculosis developed among (nondermatomal) distribution.
684 HIV-infected persons randomized to receive isoniazid or placebo (25 developed in the isoniazid arm, vs. 23 in the placebo arm) [23] .
Atypical Presentations Not Well Described
Patients receiving isoniazid had higher rates of smear-nega-
Deep-Seated Fungal Infections
tive, culture-positive disease than did those receiving placebo, but the trend was not statistically significant (10/25 vs. 5/23; The oral azoles, including fluconazole and itraconazole, are P Å .29). Rates of extrapulmonary disease were higher in the widely used in the care of persons infected with HIV. Intermitplacebo group, but this also failed to reach statistical signifitent doses are often given for oral and/or vaginal thrush. In cance (1/25 vs. 5/23; P Å .15). These trends possibly suggest addition, odynophagia is often presumed to be due to C. albia more attenuated clinical presentation in those receiving (and cans, and an azole is prescribed. This widespread use of oral failing to improve with) isoniazid therapy, but they are far too azoles has resulted -serendipitously in many instances -in preliminary to allow firm conclusions to be drawn. prophylaxis against various deep-seated fungal infections. Because the protection from these agents is incomplete even when dosing is sustained, and because the drug often is given only Cytomegalovirus intermittently, breakthrough of deep-seated fungal infection may occur.
Oral ganciclovir has been shown to decrease the rates of cytomegalovirus retinitis in patients with advanced AIDS [24] A recently reported prospective study examined rates of histoplasmosis among patients in Kansas City, Missouri, an area by Ç50%. In the largest published report, both breakthrough retinitis and colitis were seen, although the rate of colitis may of endemicity [20] . Investigators found 5 breakthrough cases in persons receiving azoles (4, fluconazole; 1, ketoconazole) have been lower among those receiving ganciclovir. No additional description of clinical differences was reported [24] . among 304 patients followed for 2. cases/rates compared to rates among patients receiving placebo. reported on the influence of the study regimen upon the suscep- 
